REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting

Core Insights - Microbot Medical Inc. is reaffirming its expectation for the FDA's decision regarding the 510(k) clearance of its LIBERTY Endovascular Robotic System during the current second quarter [1][2] - The ACCESS-PVI trial data will be presented for the first time at a podium presentation on April 2, 2025, by Dr. Francois Cornelis from Memorial Sloan Kettering Cancer Center [1][2] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on improving patient care globally [3] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [3]